BEDFORD, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that aPROMISE, its AIenabled FDA-cleared medical device software, is now available on the syngo.via platform, from Siemens Healthineers, one of the leading workstation systems. Siemens Healthineers will be demonstrating the integrated solution ...

Lantheus Holdings, Inc. (LNTH) has been gaining from its focus on pipeline development. The optimism, led by a solid first-quarter 2024 performance and strength in radiopharmaceuticals, is expected to contribute further. However, the company's dependence on third parties and macroeconomic concerns are major downsides. Over the past year, the Zacks Rank #2 (Buy) stock has lost 7.9% against the 2.9% growth of the industry. The S&P 500 has witnessed 26% growth in the said time frame. The renowned radiopharmace ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Lantheus Holdings (LNTH) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question. Lantheus Holdings is a member of our Medical group, which includes 1046 differ ...

BEDFORD, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Paul Blanchfield, President, will present at the William Blair 44th Annual Growth Stock Conference at 2:40 p.m. CT on Tuesday, June 4. To access a live webcast of the presentation, please visit the Investors section of the Company's website at ...

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. However, it isn't easy to find a great growth stock. Lantheus Holdings (LNTH) is on the list of such stocks currently recommended by our proprietary system. In addition to a favorable Growth Score, it carries a top Zacks Rank. Research shows that stocks carrying the best growth features consistently beat the market. And for stocks th ...

Lantheus Holdings (LNTH) closed the last trading session at $78.22, gaining 19.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $102.63 indicates a 31.2% upside potential. The average comprises eight short-term price targets ranging from a low of $96 to a high of $110, with a standard deviation of $5.32. While the lowest estimate indicates an increase of 22.7% from the current pr ...

It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days. Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the s ...

Jeffrey S. Humphrey, MD appointed Chief Medical Officer; Jean-Claude Provost, MD named Chief Science Officer BEDFORD, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Jeffrey S. Humphrey, MD has been appointed Chief Medical Officer (CMO) and Jean-Claude Provost, MD has been named Chief Science Officer ...

Lantheus Holdings (LNTH) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Over the past month, shares of this diagnostic imaging company have returned +26.4%, compared to the Zacks S&P 500 composite's -0.4% change. During this period, the Zacks Medical - Products industry, which Lantheus Holdings falls in, has lost 1.5%. The key question now is: What could be the stock's future d ...

Financial Data and Key Metrics Changes - Consolidated net revenue for Q1 2024 was $370 million, an increase of 23% year-over-year [25] - Gross profit margin for Q1 was 68.8%, an increase of 14 basis points [27] - Reported net income for Q1 was $131.1 million, with adjusted net income at $118.3 million, reflecting a 15.8% increase [29] - Fully diluted earnings per share for Q1 were $1.87, with adjusted earnings per share at $1.69, marking a 15.2% increase [29] Business Line Data and Key Metrics Changes - PYLARIFY generated net sales of $259 million, up over 32% from the prior year, driven by an expanding PSMA PET imaging market [12] - DEFINITY maintained strong momentum with Q1 net sales of approximately $77 million, up 11% year-over-year [16] - Precision Diagnostics revenue was $104.2 million, a 9% increase, with TechneLite revenue at $21.7 million, up 3.5% [26] Market Data and Key Metrics Changes - The PSMA PET imaging market is experiencing significant growth, with increased utilization among existing prescribers [41] - The company is actively expanding its PMF network, now with 58 active sites, to meet growing demand [65] Company Strategy and Development Direction - The company aims to maximize the value of its existing portfolio while expanding its pipeline through business development and M&A [5] - Strategic partnerships are being formed to ensure continued access to PYLARIFY and to mitigate the impact of potential payment changes [13][51] - The company is focused on lifecycle management strategies for PYLARIFY to maintain its market leadership [84] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving over $1 billion in PYLARIFY sales for 2024, positioning it as the first PET imaging agent to reach blockbuster status [50] - The company is optimistic about the future of the radiopharmaceutical field, citing significant near and long-term potential [22] - Management is closely monitoring industry developments and is prepared to adapt strategies as needed [91] Other Important Information - The company has a strong liquidity position with cash and cash equivalents totaling $718.3 million [30] - The company is committed to investing in long-term growth drivers while maintaining a robust financial profile [22] Q&A Session Summary Question: Dynamics in the underlying marketplace for PYLARIFY - Management noted that PYLARIFY's usage is expanding, particularly among existing customers, with increased referrals and clinical trial use [40] Question: Impact of strategic partnerships on guidance - Management indicated that while partnerships are important, the guidance is primarily based on the US market and existing customer growth [45] Question: Percentage of market impacted by transitional pass-through - Management clarified that TPT affects approximately 20% of PYLARIFY revenues, concentrated in hospital settings [51] Question: Sales cadence and potential impact from transitional pass-through - Management expects Q1 to show the highest sequential improvement, with a natural seasonal decline in subsequent quarters [61] Question: Plans for capital allocation - Management emphasized a focus on business development and internal project advancement, leveraging strong cash flow for strategic opportunities [78]